Insider Trading April 6, 2026

Arteris Vice President Sells 3,649 Shares to Cover RSU Taxes; Transaction Totals $64,415

Sale follows strong share appreciation and a Q4 2025 beat in revenue and EPS expectations

By Derek Hwang AIP
Arteris Vice President Sells 3,649 Shares to Cover RSU Taxes; Transaction Totals $64,415
AIP

Paul L. Alpern, Vice President and General Counsel of Arteris, Inc. (NASDAQ: AIP), sold 3,649 shares of common stock on April 2, 2026, in transactions executed at $17.6528 per share, totaling $64,415. The disposals were carried out to satisfy tax obligations tied to the release of restricted stock units and were not described as discretionary trades. Arteris has rallied 205% over the past year and recently reported fourth-quarter 2025 results that exceeded consensus revenue and EPS estimates.

Key Points

  • Paul L. Alpern, Arteris VP and General Counsel, sold 3,649 shares at $17.6528 on April 2, 2026, for total proceeds of $64,415.
  • The sales were executed to satisfy tax obligations related to the release of restricted stock units and were not described as discretionary trades; Alpern retains 86,386 shares after the transactions.
  • Arteris shares have climbed approximately 205% over the past year and the company reported Q4 2025 revenue of $20.1 million and EPS of -$0.05, both ahead of expectations; InvestingPro flags the stock as appearing overvalued based on Fair Value metrics.

Paul L. Alpern, who serves as Vice President and General Counsel at Arteris, Inc. (NASDAQ: AIP), completed a series of stock sales on April 2, 2026, disposing of 3,649 shares of the company's common stock.

The sales were carried out at a per-share price of $17.6528, producing proceeds of $64,415 in aggregate. Company filings indicate the transactions were executed to cover tax liabilities arising from the release of restricted stock units rather than as discretionary stock sales.

Following the April 2 transactions, Alpern retains direct ownership of 86,386 shares in Arteris, Inc., according to the reported holdings.


These insider sales come as Arteris shares have posted substantial gains in the trailing 12 months, rising roughly 205% and most recently trading at $18.24. Independent Fair Value metrics cited by InvestingPro show the stock appears overvalued at current levels, according to the analysis reported alongside the transaction details.

Investors may also be weighing the company's latest quarterly performance. Arteris reported fourth-quarter 2025 revenue of $20.1 million, surpassing the $18.55 million analysts had expected. The company posted an adjusted earnings per share of -$0.05 for the quarter, which was ahead of the forecasted -$0.07.

The quarterly results were described as a positive surprise relative to analyst expectations and attracted heightened investor interest following the announcement. The favorable variance to consensus encompassed both the revenue line and EPS, according to the reported figures.

Additional investor resources referenced in connection with the filing include InvestingPro, which is noted as offering 10 additional exclusive tips for AIP along with financial health scores and detailed metrics intended to assist investors in assessment and decision-making.


Observers reviewing the filing and recent company updates should note the explicit purpose of the insider sales - tax obligations tied to vested restricted stock units - and the post-transaction direct ownership level disclosed by Alpern. Outside of those items and the published quarterly results, the filing provides no further commentary on future insider intentions or company guidance.

Risks

  • The insider sale was undertaken to meet tax obligations from vested restricted stock units; this introduces no explicit statement of confidence or lack thereof and should not be interpreted as a discretionary vote on valuation.
  • InvestingPro's Fair Value analysis indicates the stock may be overvalued at current levels, which could present valuation risk for equity investors tracking the company.
  • While Q4 2025 results beat revenue and EPS estimates, the company still reported a negative EPS for the quarter, indicating ongoing profitability or margin challenges that could affect investor sentiment.

More from Insider Trading

Penumbra Director Executes $32,822 Stock Sale Amid Deal and Upbeat Quarterly Results Apr 6, 2026 Power Integrations VP Sells 313 Shares to Cover Tax Bill; Stock Up 45% YTD Apr 6, 2026 Lipocine Director Purchases 123,000 Shares Amid Mixed Clinical News Apr 6, 2026 Kinder Morgan Vice President Disposes of $203K in Class P Shares Apr 6, 2026 RA Capital Disposes $14.5M of Vor Biopharma Stock Across Early April Trades Apr 6, 2026